{"id":"alxn2030","safety":{"commonSideEffects":[{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Allergic reactions"},{"rate":"null","effect":"Pain or swelling at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by replacing the deficient enzyme in patients with mucopolysaccharidosis type I (MPS I), thereby reducing the accumulation of glycosaminoglycans in various tissues and organs.","oneSentence":"ALXN2030 is a recombinant human alpha-L-iduronidase enzyme replacement therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:46.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mucopolysaccharidosis type I (MPS I)"}]},"trialDetails":[{"nctId":"NCT06744647","phase":"PHASE2","title":"Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-03-07","conditions":"Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores","enrollment":45},{"nctId":"NCT05501717","phase":"PHASE1","title":"Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-08-16","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALXN2030","genericName":"ALXN2030","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ALXN2030 is a recombinant human alpha-L-iduronidase enzyme replacement therapy. Used for Mucopolysaccharidosis type I (MPS I).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}